However, the incorporation of GLP-1RA or sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in the care of patients with long-standing T2DM may be more challenging, especially if patients are using an already complex glucose-lowering regimen. Here, SLC5A2 is linked to type 2 diabetes mellitus.